US-based biopharmaceutical company, RAPT Therapeutics’ stock surged more than 63% during the pre-market trading session on the US stock market’s Nasdaq after GSK Plc announced its $2.2 billion equity value acquisition deal, according to the official filing.
RAPT Therapeutics’ stock jumped more than 63% to $57.45 during the premarket trading session on Nasdaq after the acquisition update, compared to $35.10 at the previous market close, according to MarketWatch data on Tuesday.
(This is a developing story. Please check back for updates.)
Read all stories by Anubhav Mukherjee
Disclaimer: This story is for educational purposes only. We advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and circumstances may vary.
